VAXCYTE INC. - COMMON STOCK

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

11 июл 2023 08:30:00 Источник Nasdaq GlobeNewswire

Vaxcyte to Present at the Jefferies Healthcare Conference

01 июн 2023 16:05:00 Источник Nasdaq GlobeNewswire

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

08 май 2023 16:03:00 Источник Nasdaq GlobeNewswire

Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

03 май 2023 16:05:00 Источник Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

21 апр 2023 17:25:10 Источник Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $500 Million Public Offering

19 апр 2023 00:26:49 Источник Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

17 апр 2023 16:05:14 Источник Nasdaq GlobeNewswire

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

17 апр 2023 06:30:00 Источник Nasdaq GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies

16 апр 2023 17:00:00 Источник Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

30 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

27 фев 2023 16:01:00 Источник Nasdaq GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

21 фев 2023 08:30:00 Источник Nasdaq GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

16 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

Vaxcyte to Present at the SVB Securities Global Biopharma Conference

07 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

05 янв 2023 08:30:00 Источник Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

07 ноя 2022 16:10:00 Источник Nasdaq GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

03 ноя 2022 08:30:01 Источник Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

28 окт 2022 16:01:00 Источник Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $600 Million Public Offering

26 окт 2022 00:20:17 Источник Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

24 окт 2022 16:01:00 Источник Nasdaq GlobeNewswire